

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

September 2023

The logo for PHARMAC, featuring the word "PHARMAC" in a large, bold, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, all-caps, sans-serif font below it. The logo is centered within a white circle that overlaps a background of stylized, concentric, wavy lines in shades of gray and white.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 September 2023	3
Section H changes to Part II	8
Index	18

Summary of decisions

EFFECTIVE 1 SEPTEMBER 2023

- Alfentanil (Medsurge) inj 0.5 mg per ml, 2 ml ampoule new listing and addition of PSS
- Amino acid formula (without phenylalanine) (PKU Build 20 Chocolate, Raspberry Lemonade, Smooth and Vanilla) powder 20 g protein, 1.7 g carbohydrate per 32 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU Build 20 Chocolate, Raspberry Lemonade, Smooth and Vanilla) powder 20 g protein, 1.7 g carbohydrate per 32 g sachet – to be delisted 1 January 2024
- Amlodipine (Vasorex) tab 2.5 mg, 5 mg and 10 mg – price increase and addition of PSS
- Amorolfine (Myconail) nail soln 5% – price increase and addition of PSS
- Amoxicillin granules for oral liq 125 mg per 5 ml (Alphamox 125) and granules for oral liq 250 mg per 5 ml (Alphamox 250) – price increase and addition of PSS
- Amoxicillin with clavulanic acid (Curam Duo 500/125) tab 500 mg with clavulanic acid 125 mg – price increase and addition of PSS
- Atenolol (Atenolol Viatrix) tab 100 mg – new listing and addition of PSS
- Atropine sulphate (Atropt) eye drops 1% – price increase and addition of PSS
- Benzylpenicillin sodium [Penicillin G] (Sandoz) inj 600 mg (1 million units) vial – price increase and addition of PSS
- Bupivacaine hydrochloride inj 5 mg per ml, 4 ml ampoule (Marcaïn Isobaric) and inj 2.5 mg per ml, 20 ml ampoule sterile pack (Marcaïn) – price increase and addition of PSS
- Calcium carbonate (Calci-Tabs) tab 1.25 g (500 mg elemental) – price increase and addition of PSS
- Clonidine (Mylan) patch 2.5 mg, 100 mcg per day and 7.5 mg, 300 mcg per day – price increase and addition of PSS
- Clonidine (Mylan) patch 5 mg, 200 mcg per day – price decrease and addition of PSS
- Colecalciferol (Clinicians) oral liq 188 mcg per ml (7,500 iu per ml) – new listing
- Colecalciferol (Puria) oral liq 188 mcg per ml (7,500 iu per ml) – to be delisted 1 March 2024
- Colestyramine (Colestyramine – Mylan) powder for oral solution 4 g sachet – new listing
- Cyproterone acetate with ethinyloestradiol (Ginet) tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – price increase and addition of PSS
- Darunavir (Darunavir Viatrix) tab 400 mg and 600 mg – price increase and addition of PSS

Summary of decisions – effective 1 September 2023 (continued)

- Desmopressin acetate (Desmopressin-PH&T) nasal spray 10 mcg per dose – price increase and addition of PSS
- Diphtheria, tetanus and pertussis vaccine (Boostrix) inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe, 1 inj pack – to be delisted 1 September 2023
- Docusate sodium (Coloxyl) tab 50 mg and 120 mg – price increase and addition of PSS
- Emulsifying ointment (Jaychem) oint BP – price increase and addition of PSS
- Ephedrine (Max Health) inj 30 mg per ml, 1 ml ampoule – price increase and addition of PSS
- Fentanyl (Biomed) inj 10 mcg per ml, 100 ml bag – price increase and addition of PSS
- Flucloxacillin (Flucil) inj 1 g vial – price increase and addition of PSS
- Gliclazide (Glizide) tab 80 mg – price increase and addition of PSS
- Glucose [Dextrose] (Biomed) inj 50%, 10 ml ampoule and 90 ml bottle – price increase and addition of PSS
- Granisetron (Deva) inj 1 mg per ml, 3 ml ampoule – addition of PSS
- Indapamide (Dapa-Tabs) tab 2.5 mg – price increase and addition of PSS
- Isosorbide mononitrate tab 20 mg (Ismo 20), tab long-acting 40 mg (Ismo 40 retard) and 60 mg (Duride) – price increase and addition of PSS
- Ispaghula (Psyllium) husk (Konsyl-D) powder for oral soln – price increase and addition of PSS
- Lacosamide (Vimpat) tab 50 mg and 100 mg – amended restriction criteria
- Lamivudine tab 100 mg (Zetlam) and tab 150 mg (Lamivudine Viatrix) – price increase and addition of PSS
- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Molaxole) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – price increase and addition of PSS
- Meningococcal (A, C, Y and W-135) conjugate vaccine (Menactra) inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial, 1 and 5 inj pack – to be delisted 1 September 2023
- Metaraminol (Torbay) inj 10 mg per ml, 1 ml ampoule – price decrease and addition of PSS
- Methylprednisolone aceponate (Advantan) crm 0.1% and oint 0.1% – price increase and addition of PSS

Summary of decisions – effective 1 September 2023 (continued)

- Montelukast (Montelukast Mylan) tab 4 mg and 10 mg – removal of PSS and to be delisted 1 February 2024
 - Montelukast (Montelukast Viatris) tab 4 mg and 10 mg – addition of PSS
 - Morphine sulphate (Biomed) inj 1 mg per ml, 100 ml bag, 10 ml syringe and 50 ml syringe – price increase and addition of PSS
 - Moxifloxacin (Moxifloxacin Kabi) inj 1.6 mg per ml, 250 ml bottle, 10 inj pack – new listing and addition of PSS
 - Moxifloxacin (Moxifloxacin Kabi) inj 1.6 mg per ml, 250 ml bottle, 1 inj pack – to be delisted 1 February 2024
 - Naphazoline hydrochloride (Naphcon Forte) eye drops 0.1%, 15 ml – delisting revoked
 - Nifedipine (Mylan (24 hr release) tab long-acting 30 mg – to be delisted 1 February 2024
 - Noradrenaline (Noradrenaline BNM) inj 1 mg per ml, 4 ml ampoule – price increase and addition of PSS
 - Nystatin (Nilstat) oral liq 100,000 u per ml – price increase and addition of PSS
 - Nystatin (Nilstat) vaginal crm 100,000 u per 5 g with applicator(s) – price increase and addition of PSS
 - Oestril (Ovestin) crm 1 mg per g with applicator – price increase and addition of PSS
 - Oestril (Ovestin) pessaries 500 mcg – price increase and addition of PSS
 - Oestril (Ovestin) tab 2 mg – price increase and addition of PSS
 - Olanzapine (Zypine ODT) tab orodispersible 5 mg and 10 mg – price increase and addition of PSS
 - Paracetamol (Gacet) suppos 125 mg, 250 mg and 500 mg – price increase and addition of PSS
 - Permethrin (A-Scabies) lotn 5% – price increase and addition of PSS
 - Permethrin (Lyderm) crm 5% – to be delisted 1 February 2024
 - Pimecrolimus (Elidel) cream 1% – price increase and addition of PSS
 - Pine tar with trolamine laurilsulfate and fluorescein (Pinetarsol) soln 2.3% with trolamine laurilsulfate and fluorescein sodium – price increase and addition of PSS
 - Poloxamer (Coloxyl) oral drops 10% - price increase and addition of PSS
 - Potassium iodate (neurotabs) tab 253 mcg (150 mcg elemental iodine) – price increase and addition of PSS
 - Pyridoxine hydrochloride (Vitamin B6 25) tab 25 mg – price increase and addition of PSS
 - Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – price increase and addition of PSS
-

Summary of decisions – effective 1 September 2023 (continued)

- Remifentanyl (Remifentanyl-AFT) inj 1 mg vial and 2 mg vial – price increase and addition of PSS
 - Rizatriptan (Rizamelt) tab orodispersible 10 mg – price increase and addition of PSS
 - Ropivacaine hydrochloride (Ropivacaine Kabi) inj 2 mg per ml, 10 ml ampoule and 20 ml ampoule, 2 mg per ml, 100 ml bag – price increase and addition of PSS
 - Ropivacaine hydrochloride (Ropivacaine Kabi) inj 7.5 mg per ml, 10 ml ampoule and 20 ml ampoule, inj 10 mg per ml, 10 ml ampoule and 20 ml ampoule – price increase and addition of PSS
 - Rosuvastatin (Rosuvastatin Viatris) tab 20 mg and 40 mg, 30 tab blister pack – to be delisted 1 April 2024
 - Rosuvastatin (Rosuvastatin Viatris) tab 5 mg and 10 mg, 30 tab blister pack – to be delisted 1 October 2024
 - Rosuvastatin (Rosuvastatin Viatris) tab 5 mg, 10 mg, 20 mg and 40 mg, 30 tab bottle pack – amended PSS date
 - Simvastatin (Simvastatin Mylan) tab 10 mg, 20 mg, 40 mg and 80 mg – to be delisted 1 February 2024
 - Simvastatin (Simvastatin Viatris) tab 10 mg, 20 mg and 80 mg – new listing and addition of PSS
 - Simvastatin (Simvastatin Viatris) tab 40 mg – price increase and addition of PSS
 - Sirolimus (Rapamune) tab 1 mg, 2 mg and oral liq 1 mg per ml – amended restriction criteria
 - Sodium citro-tartrate (Ural) grans eff 4 g sachets – price increase and addition of PSS
 - Stiripentol (Diacomit) cap 250 mg and powder for oral liq 250 mg sachet – amended restriction criteria
 - Suxamethonium citrate (Martindale) inj 50 mg per ml, 2 ml ampoule – price increase and addition of PSS
 - Temazepam (Normison) tab 10 mg – price increase and addition of PSS
 - Tenofovir disoproxil (Tenofovir Disoproxil Mylan) tab 245 mg (300 mg as a maleate) – removal of PSS and to be delisted 1 February 2024
 - Tenofovir disoproxil (Tenofovir Disoproxil Viatris) tab 245 mg (300 mg as a maleate) – addition of PSS
 - Terbinafine (Deolate) tab 250 mg – price increase and addition of PSS
 - Triamcinolone acetonide (Aristocort) crm 0.02% and oint 0.02% – price increase and addition of PSS
-

Summary of decisions – effective 1 September 2023 (continued)

- Triamcinolone acetonide (Kenalog in Orabase) paste 0.1% – price increase and addition of PSS
- Triamcinolone acetonide inj 10 mg per ml, 1 ml ampoule (Kenacort-A 10) and inj 40 mg per ml, 1 ml ampoule (Kenacort-A 40) – price increase and addition of PSS
- Ursodeoxychloric acid (Ursosan) cap 250 mg – price increase and addition of PSS
- Valganciclovir (Valganciclovir Mylan) tab 450 mg – removal of PSS and to be delisted 1 February 2024
- Valganciclovir (Valganciclovir Viatrix) tab 450 mg – addition of PSS
- Vancomycin (Mylan) inj 500 mg vial – price increase and addition of PSS
- Varicella zoster vaccine [shingles vaccine] (Zostavax) varicella zoster virus (Oka strain) live attenuated vaccine, inj 1 pack and 10 pack – to be delisted 1 September 2023

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 September 2023

ALIMENTARY TRACT AND METABOLISM

11	GLICLAZIDE (↑ price and addition of PSS) Tab 80 mg – 5% DV Feb-24 to 2026	20.10	500	Glizide
13	URSODEOXYCHOLIC ACID (↑ price and addition of PSS) → Cap 250 mg – 5% DV Feb-24 to 2026	33.95	100	Ursosan
15	ISPAGHULA (PSYLLIUM) HUSK (↑ price and addition of PSS) Powder for oral soln – 5% DV Feb-24 to 2026	20.00	500 g	Konsyl-D
15	DOCUSATE SODIUM (↑ price and addition of PSS) Tab 50 mg – 5% DV Feb-24 to 2026	3.20	100	Coloxyl
	Tab 120 mg – 5% DV Feb-24 to 2026	4.98	100	Coloxyl
15	POLOXAMER (price ↑ and addition of PSS) Oral drops 10% – 5% DV Feb-24 to 2026	4.17	30 ml	Coloxyl
16	MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (↑ price and addition of PSS) Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 5% DV Feb-24 to 2026	8.50	30	Molaxole
23	CALCIUM CARBONATE (↑ price and addition of PSS) Tab 1.25 g (500 mg elemental) – 5% DV Feb-24 to 2026	7.28	250	Calci-Tab 500
23	POTASSIUM IODATE (↑ price and addition of PSS) Tab 253 mcg (150 mcg elemental iodine) – 5% DV Feb-24 to 2026	5.99	90	NeuroTabs
25	TRIAMCINOLONE ACETONIDE (↑ price and addition of PSS) Paste 0.1% – 5% DV Feb-24 to 2026	5.49	5 g	Kenalog in Orabase
25	NYSTATIN (↑ price and addition of PSS) Oral liquid 100,000 u per ml – 5% DV Feb-24 to 2026	2.22	24 ml	Nilstat
27	PYRIDOXINE HYDROCHLORIDE (↑ price and addition of PSS) Tab 25 mg – 5% DV Feb-24 to 2026	3.43	90	Vitamin B6 25
27	COLECALCIFEROL (new listing) Oral liq 188 mcg per ml (7,500 iu per ml).....	9.00	5 ml	Clinicians

Note – Puria oral liq 188 mcg per ml (7,500 iu per ml) to be delisted from 1 March 2024.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

BLOOD AND BLOOD FORMING ORGANS

40	GLUCOSE [DEXTROSE] († price and addition of PSS)		
	Inj 50%, 10 ml ampoule – 5% DV Feb-24 to 2026	34.75	5 Biomed
	Inj 50%, 90 ml bottle – 5% DV Feb-24 to 2026	17.50	1 Biomed

CARDIOVASCULAR SYSTEM

47	ATENOLOL (new listing)		
	Tab 100 mg.....	14.20	500 Atenolol Viatris
48	AMLODIPINE († price and addition of PSS)		
	Tab 2.5 mg – 5% DV Feb-24 to 2026	1.45	90 Vasorex
	Tab 5 mg – 5% DV Feb-24 to 2026	1.21	90 Vasorex
	Tab 10 mg – 5% DV Feb-24 to 2026	1.31	90 Vasorex
49	NIFEDIPINE (delisting)		
	Tab long-acting 30 mg.....	34.10	100 Mylan (24 hr release)
	Note – Mylan (24 hr release) tab long-acting 30 mg to be delisted from 1 February 2024.		
49	CLONIDINE († price and addition of PSS)		
	Patch 2.5 mg, 100 mcg per day – 5% DV Feb-24 to 2026	11.70	4 Mylan
	Patch 7.5 mg, 300 mcg per day – 5% DV Feb-24 to 2026	17.90	4 Mylan
49	CLONIDINE († price and addition of PSS)		
	Patch 5 mg, 200 mcg per day – 5% DV Feb-24 to 2026	12.80	4 Mylan
51	INDAPAMIDE († price and addition of PSS)		
	Tab 2.5 mg – 5% DV Feb-24 to 2026	16.00	90 Dapa-Tabs
52	ROSUVASTATIN (amended PSS date and delisting)		
	→ Tab 5 mg – 5% DV Dec-23 Oct-24 to 2026	1.29	30 Rosuvastatin Viatris
	→ Tab 10 mg – 5% DV Dec-23 Oct-24 to 2026	1.69	30 Rosuvastatin Viatris
	→ Tab 20 mg – 5% DV Dec-23 Apr-24 to 2026	2.71	30 Rosuvastatin Viatris
	→ Tab 40 mg – 5% DV Dec-23 Apr-24 to 2026	4.55	30 Rosuvastatin Viatris
	Note – Rosuvastatin Viatris tab 20 mg (Pharmacode 2616769) and 40 mg (Pharmacode 2616777), 30 tab blister pack to be delisted from 1 April 2024. Rosuvastatin Viatris tab 5 mg (Pharmacode 2616742) and 10 mg (Pharmacode 2616750), 30 tab blister pack to be delisted from 1 October 2024.		
53	COLESTYRAMINE (new listing)		
	Powder for oral suspension 4 g sachet.....	61.50	50 Colestyramine - Mylan
53	SIMVASTATIN (new listing and addition of PSS)		
	Tab 10 mg – 5% DV Feb-24 to 2026	1.68	90 Simvastatin Viatris
	Tab 20 mg – 5% DV Feb-24 to 2026	2.54	90 Simvastatin Viatris
	Tab 80 mg – 5% DV Feb-24 to 2026	8.81	90 Simvastatin Viatris
	Note – Simvastatin Mylan tab 10 mg, 20 mg and 80 mg to be delisted from 1 February 2024.		
53	SIMVASTATIN († price and addition of PSS)		
	Tab 40 mg – 5% DV Feb-24 to 2026	4.11	90 Simvastatin Viatris
	Note – Simvastatin Mylan tab 40 mg to be delisted from 1 February 2024.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

54	ISOSORBIDE MONONITRATE (↑ price and addition of PSS)			
	Tab 20 mg – 5% DV Feb-24 to 2026	22.49	100	Ismo 20
	Tab long-acting 40 mg – 5% DV Feb-24 to 2026	9.80	30	Ismo 40 Retard
	Tab long-acting 60 mg – 5% DV Feb-24 to 2026	13.50	90	Duride
54	EPHEDRINE (↑ price and addition of PSS)			
	Inj 30 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026	34.31	10	Max Health
55	METARAMINOL (↓ price and addition of PSS)			
	Inj 10 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026	53.00	10	Torbay
55	NORADRENALINE (addition of PSS)			
	Inj 1 mg per ml, 4 ml ampoule – 5% DV Feb-24 to 2025	45.00	10	Noradrenaline BNM

DERMATOLOGICALS

67	AMOROLFINE (↑ price and addition of PSS)			
	Nail soln 5% – 5% DV Feb-24 to 2026	21.87	5 ml	MycosNail
68	PERMETHRIN (↑ price and addition of PSS)			
	Lotn 5% – 5% DV Feb-24 to 2026	4.28	30 ml	A-Scabies
	Note – Lyderm crm 5% to be delisted from 1 February 2024.			
69	EMULSIFYING OINTMENT (↑ price and addition of PSS)			
	Oint BP – 5% DV Feb-24 to 2026	2.30	100 g	Jaychem
	Note: DV limit applies to pack sizes of less than 200 g.			
70	METHYLPREDNISOLONE ACEPONATE (↑ price and addition of PSS)			
	Crn 0.1% – 5% DV Feb-24 to 2026	4.95	15 g	Advantan
	Oint 0.1% – 5% DV Feb-24 to 2026	4.95	15 g	Advantan
71	TRIAMCINOLONE ACETONIDE (↑ price and addition of PSS)			
	Crn 0.02% – 5% DV Feb-24 to 2026	6.49	100 g	Aristocort
	Oint 0.02% – 5% DV Feb-24 to 2026	6.54	100 g	Aristocort
71	PIMECROLIMUS (↑ price and addition of PSS)			
	→ Crm 1% – 5% DV Feb-24 to 2026	33.00	15 g	Elidel
72	PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN (↑ price and addition of PSS)			
	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 5% DV Feb-24 to 2026	5.41	500 ml	Pinetarsol

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

GENITO-URINARY SYSTEM

74	NYSTATIN (↑ price and addition of PSS) Vaginal crm 100,000 u per 5 g with applicator(s) – 5% DV Feb-24 to 2026	5.70	75 g	Nilstat
74	CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL (↑ price and addition of PSS) Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 5% DV Feb-24 to 2026	5.08	168	Ginet
76	OESTRIOL (↑ price and addition of PSS) Crm 1 mg per g with applicator – 5% DV Feb-24 to 2026	6.95	15 g	Ovestin
	Pessaries 500 mcg – 5% DV Feb-24 to 2026	7.55	15	Ovestin
76	SODIUM CITRO-TARTRATE (↑ price and addition of PSS) Grans eff 4 g sachets – 5% DV Feb-24 to 2026	3.50	28	Ural
81	OESTRIOL (↑ price and addition of PSS) Tab 2 mg – 5% DV Feb-24 to 2026	7.70	30	Ovestin

HORMONE PREPARATIONS

80	TRIAMCINOLONE ACETONIDE (↑ price and addition of PSS) Inj 10 mg per ml, 1 ml ampoule – 10% DV Feb-24 to 2026	21.42	5	Kenacort-A 10
	Inj 40 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026	52.63	5	Kenacort-A 40
82	TETRACOSACTIDE [TETRACOSACTRIN] (↑ price) Inj 250 mcg per ml, 1 ml ampoule.....	86.25	1	Synacthen

INFECTIONS

87	DESMOPRESSIN ACETATE (↑ price and addition of PSS) Nasal spray 10 mcg per dose – 5% DV Feb-24 to 2026	34.95	6 ml	Desmopressin-PH&T
92	AMOXICILLIN (↑ price and addition of PSS) Grans for oral liq 125 mg per 5 ml – 5% DV Feb-24 to 2026	2.22	100 ml	Alphamox 125
	Grans for oral liq 250 mg per 5 ml – 5% DV Feb-24 to 2026	2.81	100 ml	Alphamox 250
92	AMOXICILLIN WITH CLAVULANIC ACID (↑ price and addition of PSS) Tab 500 mg with clavulanic acid 125 mg – 5% DV Feb-24 to 2026	1.59	10	Curam Duo 500/125
92	BENZYLPENICILLIN SODIUM [PENICILLIN G] (↑ price and addition of PSS) Inj 600 mg (1 million units) vial – 5% DV Feb-24 to 2026	16.50	10	Sandoz

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

92	FLUCLOXACILLIN (↑ price and addition of PSS) Inj 1 g vial – 5% DV Feb-24 to 2026	6.00	5	Flucil
93	MOXIFLOXACIN (new listing and addition of PSS) → Inj 1.6 mg per ml, 250 ml bottle – 5% DV Feb-24 to 2026	413.40	10	Moxifloxacin Kabi
	Note – Moxifloxacin inj 1.6 mg per ml, 250 ml bottle, 1 inj pack to be delisted from 1 February 2024.			
95	VANCOMYCIN (↑ price and addition of PSS) → Inj 500 mg vial – 5% DV Feb-24 to 2026	3.38	1	Mylan
98	TERBINAFINE (↑ price and addition of PSS) Tab 250 mg – 5% DV Feb-24 to 2026	8.97	84	Deolate
102	LAMIVUDINE (↑ price and addition of PSS) → Tab 150 mg – 5% DV Feb-24 to 2026	98.00	60	Lamivudine Viatris
103	DARUNAVIR (↑ price and addition of PSS) → Tab 400 mg – 5% DV Feb-24 to 2026 → Tab 600 mg – 5% DV Feb-24 to 2026	150.00 225.00	60 60	Darunavir Viatris Darunavir Viatris
104	LAMIVUDINE (↑ price and addition of PSS) Tab 100 mg – 5% DV Feb-24 to 2026	12.06	28	Zetlam
105	TENOFOVIR DISOPROXIL (delisting and removal of PSS) Tab 245 mg (300 mg as a maleate) – 5% DV Dec-22 to 2025 31/08/2023	15.00	30	Tenofovir Disoproxil Mylan
	Note – Tenofovir Disoproxil Mylan tab 245 mg (300 mg as a maleate) to be delisted from 1 February 2024.			
105	TENOFOVIR DISOPROXIL (addition of PSS) Tab 245 mg (300 mg as a maleate) – 5% DV Sep-23 to 2025	15.00	30	Tenofovir Disoproxil Viatris
105	VALGANCICLOVIR (delisting and removal of PSS) → Tab 450 mg – 5% DV Dec-21 to 2024 31/08/2023	132.00	60	Valganciclovir Mylan
	Note – Valganciclovir Mylan tab 450 mg to be delisted from 1 February 2024.			
105	VALGANCICLOVIR (addition of PSS) → Tab 450 mg – 5% DV Sep-23 to 2024	132.00	60	Valganciclovir Viatris

MUSCULOSKELETAL SYSTEM

115	SUXAMETHONIUM CHLORIDE (↑ price and addition of PSS) Inj 50 mg per ml, 2 ml ampoule – 5% DV Feb-24 to 2026	35.40	10	Martindale
-----	---	-------	----	-------------------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

NERVOUS SYSTEM

120	BUPIVACAINE HYDROCHLORIDE († price and addition of PSS) Inj 5 mg per ml, 4 ml ampoule – 5% DV Feb-24 to 2026	62.50	5	Marcaïn Isobaric
	Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 5% DV Feb-24 to 2026	28.00	5	Marcaïn
122	ROPIVACAINE HYDROCHLORIDE († price and addition of PSS) Inj 2 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026	9.80	5	Ropivacaine Kabi
	Inj 2 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026	10.25	5	Ropivacaine Kabi
	Inj 2 mg per ml, 100 ml bag – 5% DV Feb-24 to 2026	32.85	5	Ropivacaine Kabi
	Inj 2 mg per ml, 200 ml bag – 5% DV Feb-24 to 2026	43.40	5	Ropivacaine Kabi
	Inj 7.5 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026	11.00	5	Ropivacaine Kabi
	Inj 7.5 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026	13.50	5	Ropivacaine Kabi
	Inj 10 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026	11.75	5	Ropivacaine Kabi
	Inj 10 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026	17.60	5	Ropivacaine Kabi
123	PARACETAMOL († price and addition of PSS) Suppos 125 mg – 5% DV Feb-24 to 2026	4.29	10	Gacet
	Suppos 250 mg – 5% DV Feb-24 to 2026	5.39	10	Gacet
	Suppos 500 mg – 5% DV Feb-24 to 2026	16.55	50	Gacet
123	ALFENTANIL (new listing and addition of PSS) Inj 0.5 mg per ml, 2 ml ampoule – 5% DV Feb-24 to 2026	8.99	5	Medsurge
	Note – Hameln inj 0.5 mg per ml, 2 ml ampoule to be delisted from 1 February 2024.			
123	FENTANYL († price and addition of PSS) Inj 10 mcg per ml, 100 ml bag – 5% DV Feb-24 to 2026	114.25	5	Biomed
124	MORPHINE SULPHATE († price and addition of PSS) Inj 1 mg per ml, 100 ml bag – 5% DV Feb-24 to 2026	114.25	5	Biomed
	Inj 1 mg per ml, 10 ml syringe – 5% DV Feb-24 to 2026	27.25	5	Biomed
	Inj 1 mg per ml, 50 ml syringe – 5% DV Feb-24 to 2026	63.75	5	Biomed
125	REMIFENTANIL († price and addition of PSS) Inj 1 mg vial – 5% DV Feb-24 to 2026	14.95	5	Remifentanil-AFT
	Inj 2 mg vial – 5% DV Feb-24 to 2026	20.95	5	Remifentanil-AFT

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

127	LACOSAMIDE (amended restriction criteria – amended criteria shown only)			
	→ Tab 50 mg.....	25.04	14	Vimpat
	→ Tab 100 mg.....	50.06	14	Vimpat
		200.24	56	Vimpat
	→ Tab 150 mg.....	75.10	14	Vimpat
		300.40	56	Vimpat
	→ Tab 200 mg.....	400.55	56	Vimpat
	→ Inj 10 mg per ml, 20 ml vial			
	Restricted			
	Initiation			
	<i>Re-assessment required after 15 months</i>			
	Both:			
	1 Patient has focal epilepsy; and			
	2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam, and any two of carbamazepine, lamotrigine, and phenytoin sodium (see Note).			
	Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate.			
	Those who can father children are not required to trial sodium valproate.			
128	STIRIPENTOL (amended restriction criteria – amended criteria shown only)			
	→ Cap 250 mg	509.29	60	Diacomit
	→ Powder for oral liq 250 mg sachet	509.29	60	Diacomit
	Restricted			
	Initiation			
	Paediatric neurologist			
	<i>Re-assessment required after 6 months</i> Both:			
	1 Patient has confirmed diagnosis of Dravet syndrome; and			
	2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.			
	Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.			
130	RIZATRIPTAN (↑ price and addition of PSS)			
	Tab orodispersible 10 mg – 5% DV Feb-24 to 2026	4.84	30	Rizamelt
130	GRANISETRON (addition of PSS)			
	Inj 1 mg per ml, 3 ml ampoule – 5% DV Feb-24 to 2026	1.20	1	Deva
132	OLANZAPINE (↑ price and addition of PSS)			
	Tab orodispersible 5 mg – 5% DV Feb-24 to 2026	2.42	28	Zypine ODT
	Tab orodispersible 10 mg – 5% DV Feb-24 to 2026	2.89	28	Zypine ODT
132	QUETIAPINE (↑ price and addition of PSS)			
	Tab 25 mg – 5% DV Feb-24 to 2026	2.36	90	Quetapel
	Tab 100 mg – 5% DV Feb-24 to 2026	6.40	90	Quetapel
	Tab 200 mg – 5% DV Feb-24 to 2026	10.97	90	Quetapel
	Tab 300 mg – 5% DV Feb-24 to 2026	15.83	90	Quetapel
135	TEMAZEPAM (↑ price and addition of PSS)			
	Tab 10 mg – 5% DV Feb-24 to 2026	1.40	25	Normison

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

166	TACROLIMUS (amended restriction criteria)			
	→ Cap 0.5 mg	49.60	100	Tacrolimus Sandoz
	→ Cap 0.75 mg	99.30	100	Tacrolimus Sandoz
	→ Cap 1 mg	84.30	100	Tacrolimus Sandoz
	→ Cap 5 mg	248.20	50	Tacrolimus Sandoz
	→ Inj 5 mg per ml, 1 ml ampoule			
	Restricted			
	Initiation – non-transplant indications*			
	Any specialist			
	Both:			
	1 Patient requires long-term systemic immunosuppression; and			
	2 Either:			
	2.1 Ciclosporin has been trialed and discontinued treatment because of unacceptable side effects or inadequate clinical response; or			
	2.2 Patient is a child with nephrotic syndrome*.			
	Note: Indications marked with * are unapproved indications			
237	SIROLIMUS (amended restriction criteria – amended criteria shown only)			
	→ Tab 1 mg.....	749.99	100	Rapamune
	→ Tab 2 mg.....	1,499.99	100	Rapamune
	→ Oral liq 1 mg per ml.....	449.99	60 ml	Rapamune
	Restricted			
	Initiation – refractory seizures associated with tuberous sclerosis complex*			
	Neurologist			
	<i>Re-assessment required after 6 months</i>			
	All of the following:			
	1 Patient has epilepsy with a background of documented tuberous sclerosis complex*; and			
	2 Either:			
	2.1 Both:			
	2.1.1 Vigabatrin has been trialed and has not adequately controlled seizures; and			
	2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or			
	2.2 Both:			
	2.2.1 Vigabatrin is contraindicated; and			
	2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and			
	3 Seizures have a significant impact on quality of life; and			
	4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.			
	Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, and topiramate. Those who can father children are not required to trial sodium valproate.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

246	MONTELUKAST (delisting and removal of PSS) Tab 4 mg – 5% DV Dec-22 to 2025-31/08/2023	3.10	28	Montelukast Mylan
	Tab 10 mg – 5% DV Dec-22 to 2025-31/08/2023	2.90	28	Montelukast Mylan
Note – Montelukast Mylan tab 4 mg and 10 mg to be delisted from 1 February 2024.				

246	MONTELUKAST (addition of PSS) Tab 4 mg – 5% DV Sep-23 to 2025	3.10	28	Montelukast Viatris
	Tab 10 mg – 5% DV Sep-23 to 2025	2.90	28	Montelukast Viatris

SENSORY ORGANS

225	ATROPINE SULPHATE (↑ price and addition of PSS) Eye drops 1% – 5% DV Feb-24 to 2026	18.27	15 ml	Atropt
253	NAPHAZOLINE HYDROCHLORIDE (delisting revoked) Eye drops 0.1%.....	4.15	15 ml	Naphcon Forte
Note – Naphcon Forte Eye drops 0.1% to be delisted from 1 September 2023.				

SPECIAL FOODS

284	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing) → Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet.....	898.56	30	PKU Build 20 Chocolate PKU Build 20 Raspberry Lemonade PKU Build 20 Smooth PKU Build 20 Vanilla
Note – Amino acid formula (without phenylalanine) (PKU Build 20 Chocolate, Raspberry Lemonade, Smooth and Vanilla) powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delisted from 1 January 2024.				

VACCINES

286	DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE (delisting) → Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 0% DV Oct-20 to 2024	0.00	1	Boostrix
Note – Boostrix, 1 inj pack, to be delisted from 1 September 2023				

286	MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE (delisting) → Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial.....	0.00	1 5	Menactra Menactra
Note – Menactra inj 1 and 5 pack, to be delisted from 1 October 2023				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2023 (continued)

294	VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] (delisting)		
	→ Varicella zoster virus (Oka strain) live		
	attenuated vaccine [shingles vaccine].....	0.00	1
			Zostavax
			10
			Zostavax
	Note – Zostavax inj 1 and 5 inj pack to be delisted from 1 September 2023		

Index

Pharmaceuticals and brands

A		
Advantan	10	
ALFENTANIL	13	
Alphamox 125	11	
Alphamox 250	11	
AMINO ACID FORMULA (WITHOUT PHENYLALANINE).....	16	
AMLODIPINE.....	9	
AMOROLFINE.....	10	
AMOXICILLIN	11	
AMOXICILLIN WITH CLAVULANIC ACID.....	11	
Aristocort.....	10	
A-Scabies.....	10	
ATENOLOL.....	9	
Atenolol Viatris	9	
ATROPINE SULPHATE.....	16	
Atropt	16	
B		
BENZYLPENICILLIN SODIUM [PENICILLIN G].....	11	
Boostrix.....	16	
BUPIVACAINE HYDROCHLORIDE	13	
C		
Calci-Tab 500	8	
CALCIUM CARBONATE	8	
Clinicians	8	
CLONIDINE	9	
COLECALCIFEROL	8	
COLESTYRAMINE	9	
Colestyramine - Mylan	9	
Coloxyl	8	
Curam Duo 500/125	11	
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL.....	11	
D		
Dapa-Tabs	9	
DARUNAVIR.....	12	
Darunavir Viatris.....	12	
Deolate	12	
DESMOPRESSIN ACETATE	11	
Desmopressin-PH&T.....	11	
DEXTROSE.....	9	
Diacomit	14	
DIPHThERIA, TETANUS AND PERTUSSIS VACCINE.....	16	
DOCUSATE SODIUM	8	
Duride.....	10	
E		
Elidel.....	10	
EMULSIFYING OINTMENT	10	
EPHEDRINE	10	
F		
FENTANYL	13	
Flucil.....	12	
FLUCLOXACILLIN.....	12	
G		
Gacet.....	13	
Ginet.....	11	
GLICLAZIDE	8	
Glizide.....	8	
GLUCOSE [DEXTROSE].....	9	
GRANISETRON	14	
I		
INDAPAMIDE	9	
Ismo 20	10	
Ismo 40 Retard	10	
ISOSORBIDE MONONITRATE	10	
ISPAHULA (PSYLLIUM) HUSK	8	
K		
Kenacort-A 10.....	11	
Kenacort-A 40.....	11	
Kenalog in Orabase	8	
Konsyl-D.....	8	
L		
LACOSAMIDE	14	
LAMIVUDINE.....	12	
Lamivudine Viatris.....	12	
M		
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE	8	
Marcaïn	13	
Marcaïn Isobaric	13	
Menactra	16	
MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE	16	
METARAMINOL.....	10	
METHYLPREDNISOLONE ACEPONATE	10	
Molaxole	8	
MONTELUKAST	16	
Montelukast Mylan.....	16	
Montelukast Viatris.....	16	
MORPHINE SULPHATE	13	
MOXIFLOXACIN	12	
Moxifloxacin Kabi.....	12	
Mycosyl	10	
MycoNail	10	
Mylan (24 hr release).....	9	
N		
NAPHAZOLINE HYDROCHLORIDE	16	
Naphcon Forte	16	
NeuroTabs	8	

Index

Pharmaceuticals and brands

NIFEDIPINE	9
Nilstat	8, 11
NORADRENALINE	10
Noradrenaline BNM	10
Normison	14
NYSTATIN	8, 11
O	
OESTRIOL	11
OLANZAPINE	14
Ovestin	11
P	
PARACETAMOL	13
PENICILLIN G	11
PERMETHRIN	10
PIMECROLIMUS	10
Pinetarsol	10
PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESC EIN	10
PKU Build 20 Chocolate	16
PKU Build 20 Raspberry Lemonade	16
PKU Build 20 Smooth	16
PKU Build 20 Vanilla	16
POLOXAMER	8
POTASSIUM IODATE	8
PYRIDOXINE HYDROCHLORIDE	8
Q	
Quetapel	14
QUETIAPINE	14
R	
Rapamune	15
REMIFENTANIL	13
Remifentanil-AFT	13
Rizamelt	14
RIZATRIPTAN	14
ROPIVACAINE HYDROCHLORIDE	13
Ropivacaine Kabi	13
ROSUVASTATIN	9
Rosuvastatin Viatris	9
S	
SHINGLES VACCINE	17
SIMVASTATIN	9
Simvastatin Viatris	9
SIROLIMUS	15
SODIUM CITRO-TARTRATE	11
STIRIPENTOL	14
SUXAMETHONIUM CHLORIDE	12
Synacthen	11
T	
TACROLIMUS	15
Tacrolimus Sandoz	15
TEMAZEPAM	14
TENOFOVIR DISOPROXIL	12
Tenofovir Disoproxil Mylan	12
Tenofovir Disoproxil Viatris	12
TERBINAFINE	12
TETRACOSACTIDE [TETRACOSACTRIN]	11
TETRACOSACTRIN	11
Torbay	10
TRIAMCINOLONE ACETONIDE	8, 10, 11
U	
Ural	11
URSODEOXYCHOLIC ACID	8
Ursosan	8
V	
VALGANCICLOVIR	12
Valganciclovir Mylan	12
Valganciclovir Viatris	12
VANCOMYCIN	12
VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]	17
Vasorex	9
Vimpat	14
Vitamin B6 25	8
Z	
Zetlam	12
Zostavax	17
Zypine ODT	14

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

